Short answer
Nurix Therapeutics, Inc. (NRIX) filed its Q3 2025 10-Q quarterly report on Oct 9, 2025 for the quarter ended Aug 31, 2025. Quarterly revenue was $8M (down 37.3% year over year) with net income of −$86M.
Q3 2025 key financials · XBRL
- Revenue
- $8M
- −37.3% YoY · −82.1% QoQ
- Net income
- −$86M
- −76.5% YoY · −98.8% QoQ
- Operating margin
- -1157.7%
- EPS (diluted)
- −$1.03
- −56.1% YoY · −98.1% QoQ
Source: XBRL data from the Nurix Therapeutics, Inc. (NRIX) Q3 2025 10-Q on SEC EDGAR. USD.
Nurix Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors explicitly identified; financial risks updated with net loss $186.2M for nine months ended August 31, 2025 vs prior year
- Most materially updated risk: cash and equivalents $428.8M as of August 31, 2025, sufficient for next 12 months but additional funding needs uncertain
- Regulatory risk: early-stage drug candidates require extensive and costly clinical trials with potential delays from FDA, EMA, or other authorities
- Operational risk: clinical trial delays possible from patient enrollment challenges, supply issues, regulatory feedback, and macroeconomic disruptions
- Financial risk: dependence on equity offerings, debt, and collaborations for capital; failure to raise funds may force program delays or relinquishment of rights
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nurix Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.